EANM procedure guidelines for radionuclide therapy with
Lutetium
Nuclear medicine
PSMA
Prostate cancer
Radionuclide therapy
Theranostics
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
31
05
2019
accepted:
13
08
2019
pubmed:
24
8
2019
medline:
12
9
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can be identified by PSMA-ligand imaging, which has already become clinically accepted in several countries in- and outside Europe. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (
Identifiants
pubmed: 31440799
doi: 10.1007/s00259-019-04485-3
pii: 10.1007/s00259-019-04485-3
doi:
Substances chimiques
Antigens, Surface
0
Ligands
0
Radioisotopes
0
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2536-2544Commentaires et corrections
Type : CommentIn
Références
J Nucl Med. 2019 Jul;60(7):937-943
pubmed: 31263080
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19
pubmed: 29026946
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479
pubmed: 28337529
Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68
pubmed: 28613198
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
EJNMMI Res. 2018 Apr 12;8(1):32
pubmed: 29651569
Radiat Oncol. 2011 Sep 27;6:125
pubmed: 21951317
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508
pubmed: 29247284
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
AJR Am J Roentgenol. 2019 Aug;213(2):275-285
pubmed: 30995089
J Nucl Med. 2019 Apr;60(4):517-523
pubmed: 30291192
Oncotarget. 2016 Mar 15;7(11):12477-88
pubmed: 26871285
Med Phys. 2018 May;45(5):2318-2324
pubmed: 29577338
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194
pubmed: 28801787
Clin Nucl Med. 2018 Oct;43(10):728-734
pubmed: 30059428
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847-56
pubmed: 18427807
Nuklearmedizin. 2017;56(6):219-224
pubmed: 29533417
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Oncotarget. 2017 Oct 7;8(61):103108-103116
pubmed: 29262549
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):81-91
pubmed: 27506431
EJNMMI Res. 2018 Jul 3;8(1):56
pubmed: 29971556
J Radiol Prot. 2016 Jun;36(2):269-78
pubmed: 27089552
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441
pubmed: 29785514
J Urol. 2016 Aug;196(2):382-91
pubmed: 26964917
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
J Nucl Med. 2016 Sep;57(9):1334-8
pubmed: 27056618
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2017 Mar;58(3):445-450
pubmed: 27660138
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):243-246
pubmed: 29134280
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454
pubmed: 28488028
J Nucl Med. 2018 May;59(5):795-802
pubmed: 29326358
J Nucl Med. 2015 Feb;56(2):293-8
pubmed: 25613537
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):352-360
pubmed: 28440324
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Nucl Med. 2018 Mar;59(3):459-465
pubmed: 28798031
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):192-200
pubmed: 20799035
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800
pubmed: 28083690
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S58-63
pubmed: 20171519